<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02971839</url>
  </required_header>
  <id_info>
    <org_study_id>CP656.2001</org_study_id>
    <nct_id>NCT02971839</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations</brief_title>
  <official_title>A Phase 2, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CTP-656 With an Open-Label Active Comparator in Patients With Cystic Fibrosis With CFTR Gating Mutations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of CTP-656 in patients with cystic fibrosis
      (CF) who have a cystic fibrosis transmembrane conductance regulator (CFTR) gating mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, parallel-group, double-blind, placebo controlled multicenter study to
      evaluate the safety and efficacy of CTP-656 in CF patients with CFTR gating mutations,
      compared to Kalydeco, for a total of 28 days. Subjects will be randomized to receive either
      double-blind CTP-656 or placebo, or open-label Kalydeco.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Decision by Sponsor.
  </why_stopped>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in sweat chloride at Day 28</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percent predicted FEV1 at Day 28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CFQ-R Respiratory Domain at Day 28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>CTP-656, 20 mg, QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet dosed once-daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-656, 100 mg, QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet dosed once-daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-656, 150 mg, QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet dosed once-daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kalydeco, 150 mg Tablet (open label)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg, oral tablet dosed twice-daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Oral Tablet, QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral tablet dosed once-daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-656, 20 mg (QD)</intervention_name>
    <arm_group_label>CTP-656, 20 mg, QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-656, 100 mg (QD)</intervention_name>
    <arm_group_label>CTP-656, 100 mg, QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-656, 150 mg (QD)</intervention_name>
    <arm_group_label>CTP-656, 150 mg, QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (QD)</intervention_name>
    <arm_group_label>Placebo, Oral Tablet, QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kalydeco, 150 mg Tablet (BID; open-label)</intervention_name>
    <arm_group_label>Kalydeco, 150 mg Tablet (open label)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Has a confirmed diagnosis of CF with at least one allele of the following CFTR gating
             mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, and S549R.

          -  Has been stable on Kalydeco therapy for at least 3 months prior to screening

          -  Has FEV1 â‰¥ 60% of predicted normal for age, sex, and height at screening and baseline
             (Day 1) assessments

          -  Weighs at least 40 kg at screening

          -  Patients of either gender and women of childbearing potential must be willing to use a
             medically highly effective form of birth control during the treatment period and 30
             days after the last dose of study treatment.

        Exclusion Criteria:

          -  Acute upper respiratory infection or lower respiratory infection, pulmonary
             exacerbation, or changes in therapy within 4 weeks of study treatment

          -  Uncontrolled type 2 diabetes, or uncontrolled CF-related diabetes

          -  History of hepatitis C or chronic active hepatitis B infection

          -  History of pulmonary tuberculosis, non-tuberculosis mycobacterial infections or
             allergic bronchopulmonary aspergillosis (ABPA) treated during screening or within 2
             years prior to screening

          -  Colonization with B. cenocepacia, B. dolosa, B. multivorans, and/or M. abcessus within
             2 years prior to Screening

          -  Abnormal liver function

          -  History of abnormal renal function

          -  History of prolonged QTcF &gt; 450 msec for males or QTcF &gt; 470 msec for females

          -  History of solid organ or hematological transplantation

          -  Using any inhibitor or inducer of cytochrome P450/3A during the study or within 30
             days of screening

          -  Women who are pregnant or lactating, or have plans to become pregnant during the study
             or within 1 month following the last dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Health</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2016</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

